Forte Biosciences reported a Q1 GAAP loss of $1.24 per share and held $58.2 million in cash at quarter-end.
Forte Biosciences reported a first-quarter GAAP loss of $1.24 per share, reflecting ongoing operational costs and investment in its pipeline. The company ended the period with $58.2 million in cash and cash equivalents, providing a runway for near-term development.
The loss aligns with expectations for early-stage biotech firms, though no prior quarterly consensus was publicly disclosed. As of March, Forte had 13.9 million common shares and 4.0 million prefunded warrants outstanding, unchanged from recent filings.
No immediate market reaction was detailed in the release.